Jiangsu Nhwa Pharmaceutical: Notice on completing the filing and registration procedure for the “Amendment to the Articles of Association”
Jiangsu Nhwa Pharmaceutical: Notice on Obtaining a Notice of Approval for Supplementary Applications for Alfentanyl Hydrochloride Injection Drugs
Enhua Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Enhua Pharmaceutical: Legal Opinion of the 2023 Annual General Meeting of Shareholders of Jiangsu Enhua Pharmaceutical Co., Ltd.
Enhua Pharmaceutical: Implementation Rules of the Special Committee of the Board of Directors (revised by the 10th meeting of the 6th Board of Directors of the Company on April 19, 2024)
Enhua Pharmaceutical: Prompt Announcement on Convening the 2023 Annual General Meeting of Shareholders
Enhua Pharmaceutical: Announcement on the actual controller's renewal of the concerted action agreement
Enhua Pharmaceutical: 2023 Supervisory Board Report
Enhua Pharmaceutical: Rules of Procedure for the Board of Directors (Revised Draft)
Enhua Pharmaceutical: Internal Control Self-Assessment Report
Enhua Pharmaceutical: Announcement on Using Some Idle Own Funds for Cash Management
Enhua Pharmaceutical: Shareholder return plan for the next three years (2024-2026)
Enhua Pharmaceutical: Special Meeting System for Independent Directors
Enhua Pharmaceutical: Amendment to the Constitution of Jiangsu Enhua Pharmaceutical Co., Ltd.
Enhua Pharmaceutical: Notice of Annual General Meeting of Shareholders
Enhua Pharmaceutical: Report on the Audit Committee\'s supervision of the performance of accounting firms in 2023
Enhua Pharmaceutical: Announcement on the signing of an exclusive product commercialization license and cooperation agreement by a wholly-owned subsidiary
Enhua Pharmaceutical: Announcement on independent directors voluntarily waiving receiving independent directors\' allowances
Enhua Pharmaceutical: Notice on Receiving the “Drug Clinical Trial Approval Notice” for Class 1 Chemical
Enhua Pharmaceutical: Notice on Receiving the “Notice of Approval for Drug Clinical Trials” for Class 2 Chemical Drugs
No Data